BOULDER, CO, November 14, 2017 – AmideBio LLC, a privately held biopharmaceutical company, announced today that Charles A. Stanley MD will join its scientific advisory board. Dr. Stanley is a world- renowned expert on disorders of insulin regulation in children. He founded the Congenital Hyperinsulinism Center at Children’s Hospital of Philadelphia, where he works. He has helped define the various types of hyperinsulinism (HI) and pioneered best practices for diagnosis and treatment of congenital HI.
“We are honored to have Dr. Charles A. Stanley join our scientific advisory board and support us in the development of AmideBio’s thermostable, soluble and pumpable glucagons,” said Dr. Misha Plam, President and CEO of AmideBio. “Dr. Stanley’s guidance will be invaluable as we develop these important molecules as a therapeutic treatment for HI as well as for the treatment of emergency hypoglycemia and use in a bi-hormonal artificial pancreas for Type 1 and Type 2 diabetes treatment”.
Dr. Stanley has published numerous articles in journals such asThe New England Journal of Medicine, Journal of Pediatrics, Diabetes, Journal of Clinical Endocrinology and Metabolism, and The Journal of Biological Chemistry . He was recently co-editor of Monogenic Hyperinsulinemic Hypoglycemia Disorders, volume 21 of “Frontiers in Diabetes.” Additionally, Dr. Stanley has served as an editorial board member, guest editor and reviewer for more than a dozen medical journals. In conjunction with his published work, Dr. Stanley has also lectured extensively around the world about the causes and treatment of congenital hyperinsulinism and hypoglycemia (low blood sugar) in neonates and young children. He coordinated two international symposia where thought-leaders converged in Philadelphia to share their research and develop collaborations in the area of congenital hyperinsulinism and monogenic forms of diabetes. Dr. Stanley earned his bachelor’s degree in biochemical sciences from Harvard University, Cambridge, MA, and his medical degree from the University of Virginia School of Medicine, Charlottesville, VA. He completed his residency in pediatrics and a fellowship in metabolic diseases, both at Children’s Hospital of Philadelphia, Philadelphia, PA.
AmideBio is a biotechnology company leveraging its proprietary BioPureTM platform technology to deliver difficult-to-manufacture peptides cost effectively to the pharmaceutical and biotech industry, while also building a pipeline of novel biotherapeutics. AmideBio’s proprietary technology enables the rapid and economical manufacture of peptides of any length with unprecedented purity. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at metabolic, inflammatory and neurodegenerative diseases.